

Serial No. 08/817,084

13. The method according to claim 11, wherein the antagonist is a monoclonal antibody.

14. The method according to claim 9, wherein the interleukin-6 antagonist is an antibody against an interleukin-6 receptor.

15. The method according to claim 14, wherein the antagonist is an antibody against a human interleukin-6 receptor.

16. The method according to claim 14, wherein the antagonist is a monoclonal antibody.

17. The method according to claim 9, wherein the patient is a human.

18. The method according to claim 17, wherein the antagonist is administered in four divided doses of from about 1 to 1000 mg.

<sup>1</sup>  
19. A method for inhibiting synovial cell growth, comprising ~~the step of~~ administering to a patient in need thereof a pharmaceutical composition comprising an interleukin-6 antagonist and a physiologically acceptable carrier.

<sup>2</sup>  
~~20.~~ The method according to claim <sup>1</sup>~~19~~, wherein the interleukin-6 antagonist is selected from the group consisting of an interleukin-6 antibody and an interleukin-6 receptor antibody.

<sup>3</sup>  
~~21.~~ The method according to claim <sup>2</sup>~~20~~, wherein the antagonist is a monoclonal antibody.

Serial No. 08/817,084

<sup>4</sup>  
~~22~~. The method according to claim <sup>1</sup>~~19~~, wherein the patient is a human.

a) <sup>5</sup>  
~~23~~. The method according to claim <sup>4</sup>~~22~~, wherein the antagonist is administered in four divided doses of from about 1 to 1000 mg.--

---

29